الفهرس 
INDEXOnly 14 pages are availabe for public view
Abstract
Introduction: Hepatitis C virus infection one of the major health problems. In Egypt the seroprevalence was 10%, Globally WHO report 71 million persons worldwide are living with HCV. EASL and AASLD recommend sofosbuvire based therapy in treatment of HCV. Aim of the work: To evaluate the efficacy of sofosbuvir based therapy in Egyptian chronic hepatitis C patients’ and to report any side effects that might develop during treatment. Patients and methods: Our study was performed on 343 chronic HCV patients selected from the Outpatient Hepatology and Virology Clinics at Specialized Medical Hospital (SMH), Mansoura University. Enrolled as 5 groups, 1st group was 50 patients received treatment with (PEG-IFNα2a, Sofosbuvir and ribavirin) for 12 weeks. 2nd group was 91 patients received treatment with (Sofosbuvir and ribavirin) for 24 weeks. 3rd group was 19 patients received treatment with (Sofosbuvir and simprevir ± ribavirin). 4th group 143 patients received treatment with (Sofosbuvir and Daclatasvir ± ribavirin). 5th group 40 patients received treatment with (Sofosbuvir and ledipasvir ± ribavirin). Results: 1st group achieved 74% SVR12 and the commonest side effect was fatigue 67.6%. 2nd group achieved 63.7% SVR12 and most common side effect encountered was anemia 61.6%. 3rd group achieved 78.9% SVR12 and anemia 94.7%, hypersensitivity 26.3% were the commonest side effects. 4th group achieved 95.8% SVR12 and anemia 42.6%, fatigue 37.8% were the commonest side effects. 5th group achieved 100% SVR12 and was the least side effects. Conclusions: Sofosbuvir plus daclatasvir or ledipasvir with or without ribavirin for 12 or 24 weeks is effective in treating both treatment-naïve and treatment-experienced Egyptian patients with tolerable side effects. But older regimens as pegylated interferon plus sofosbuvir and ribavirin for 3 months, sofosbuvir plus ribavirin for 6 months, sofosbuvir plus simprevir ± ribavirin for 3 months were of modest efficacy and many side effects.